Table 2:

Clinical outcome measures for dogs within the Intent-to-treat population, enrolled in SOC and SOC + S trial arms.

		SOC	SOC + S
Intent to treat population		157	152
	Started SOC	149 (95%)	150 (99%)
	Completed SOC	114 (73%)	112 (74%)
	Started sirolimus treatment	N/A	92 (61%)
	Completed sirolimus treatment	N/A	64 (42%)
Reason off-study
	Disease Progression on Study	52 (33%)	83 (55%)
	Disease Progression during Follow-up Period	69 (44%)	34 (22%)
	Complicating Disease / Intercurrent Illness	13 (8%)	8 (5%)
	Follow-up period completed	9 (6%)	7 (5%)
	Refused further treatment	3 (2%)	12 (8%)
	Refused further follow up	3 (2%)	4 (3%)
	Death on Study	2 (1%)	3 (2%)
	Death during Follow-Up Period	3 (2%)	0 (0%)
	Adverse Events / Side Effects	3 (2%)	1 (<1%)
Dogs dead during the study period		146 (93%)	143 (94%)
	Dead with evidence of metastatic disease*	118 (75%)	124 (82%)
	Dead without evidence of metastatic disease	28 (18%)	19 (13%)
Dogs alive at the end of the follow-up period		6 (4%)	9 (6%)
	Alive with evidence of metastatic disease	0 (0%)	1 (<1%)
	Alive without evidence of metastatic disease	6 (4%)	8 (5%)
Dogs lost to follow-up		5 (3%)	8 (5%)

N/A: not applicable

^*clinical, imaging, or necropsy evidence